Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors.

DurĂ³n SG, Lindstrom A, Bonnefous C, Zhang H, Chen X, Symons KT, Sablad M, Rozenkrants N, Zhang Y, Wang L, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1237-41. doi: 10.1016/j.bmcl.2011.11.073. Epub 2011 Nov 25.

PMID:
22182498
2.

Identification and SAR of selective inducible nitric oxide synthase (iNOS) dimerization inhibitors.

Gahman TC, Herbert MR, Lang H, Thayer A, Symons KT, Nguyen PM, Massari ME, Dozier S, Zhang Y, Sablad M, Rao TS, Noble SA, Shiau AK, Hassig CA.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6888-94. doi: 10.1016/j.bmcl.2011.08.112. Epub 2011 Sep 8.

PMID:
21986586
3.

Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases.

Symons KT, Nguyen PM, Massari ME, Anzola JV, Staszewski LM, Wang L, Yazdani N, Dorow S, Muhammad J, Sablad M, Rozenkrants N, Bonefous C, Payne JE, Rix PJ, Shiau AK, Noble SA, Smith ND, Hassig CA, Zhang Y, Rao TS.

J Pharmacol Exp Ther. 2011 Feb;336(2):468-78. doi: 10.1124/jpet.110.172817. Epub 2010 Oct 29.

PMID:
21036913
4.
5.

Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.

Bonnefous C, Payne JE, Roppe J, Zhuang H, Chen X, Symons KT, Nguyen PM, Sablad M, Rozenkrants N, Zhang Y, Wang L, Severance D, Walsh JP, Yazdani N, Shiau AK, Noble SA, Rix P, Rao TS, Hassig CA, Smith ND.

J Med Chem. 2009 May 14;52(9):3047-62. doi: 10.1021/jm900173b.

PMID:
19374401
6.

KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.

Symons KT, Massari ME, Nguyen PM, Lee TT, Roppe J, Bonnefous C, Payne JE, Smith ND, Noble SA, Sablad M, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA.

Mol Pharmacol. 2009 Jul;76(1):153-62. doi: 10.1124/mol.109.055434. Epub 2009 Apr 13.

PMID:
19364813
7.

Alpha-mercaptoketone based histone deacetylase inhibitors.

Wash PL, Hoffman TZ, Wiley BM, Bonnefous C, Smith ND, Sertic MS, Lawrence CM, Symons KT, Nguyen PM, Lustig KD, Guo X, Annable T, Noble SA, Hager JH, Hassig CA, Malecha JW.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6482-5. doi: 10.1016/j.bmcl.2008.10.058. Epub 2008 Oct 17.

PMID:
18954984
8.

Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.

Payne JE, Bonnefous C, Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Hoffman TZ, Rao TS, Shiau AK, Malecha JW, Noble SA, Hager JH, Smith ND.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6093-6. doi: 10.1016/j.bmcl.2008.10.029. Epub 2008 Oct 11.

PMID:
18954983
9.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Payne JE, Jenkins DA, Bonnefous C, Trotter C, Wang Y, Anzola JV, Milkova EL, Hoffman TZ, Dozier SJ, Wiley BM, Saven A, Malecha JW, Davis RL, Muhammad J, Shiau AK, Noble SA, Rao TS, Smith ND, Hager JH.

Mol Cancer Ther. 2008 May;7(5):1054-65. doi: 10.1158/1535-7163.MCT-07-2347.

10.

Inhibition of inducible nitric oxide synthase expression by a novel small molecule activator of the unfolded protein response.

Symons KT, Massari ME, Dozier SJ, Nguyen PM, Jenkins D, Herbert M, Gahman TC, Noble SA, Rozenkrants N, Zhang Y, Rao TS, Shiau AK, Hassig CA.

Curr Chem Genomics. 2008 Sep 27;2:1-9. doi: 10.2174/1875397300802010001.

11.

Repair of osteochondral defects with allogeneic tissue engineered cartilage implants.

Schreiber RE, Ilten-Kirby BM, Dunkelman NS, Symons KT, Rekettye LM, Willoughby J, Ratcliffe A.

Clin Orthop Relat Res. 1999 Oct;(367 Suppl):S382-95.

PMID:
10546661

Supplemental Content

Loading ...
Support Center